Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US – Multiple Sclerosis News Today

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS).

Sativex, by GW Pharmaceuticals, is available in 25 countries — including most of Europe and Canada — as an add-on therapy for MS patients with moderate-to-severe spasticity who fail to respond to other anti-spastic treatments. It contains cannabidiol (CBD) and tetrahydrocannabinol (THC), two of the most abundant cannabinoids found in the cannabis plant.

Click here to read full article

Font Resize